- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03491397
Genicular Artery Embolization for the Treatment of Knee Osteoarthritis (GAE-OA)
Safety and Efficacy of Genicular Artery Embolization for the Treatment of Symptomatic Knee Osteoarthritis
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Santa Monica, California, United States, 90404
- Siddharth Padia, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provided informed consent
- Age ≥ 40 years and ≤ 80 years
- Life expectancy greater than 12 months
- Ineligibility for or refusal of surgical management
- Moderate-severe knee pain as determined by visual analog scale > 4
- Osteoarthritis based on xray
- Local knee tenderness
- Resistant/failed conservative treatment (e.g. NSAIDS/physical therapy/steroid joint injection)
Exclusion Criteria:• Mild knee pain as determined by visual analog scale < 4
- Chronic renal insufficiency (serum creatinine >2 mg/dL)
- Uncorrectable bleeding diathesis: international normalized ratio (INR) >1.6, Platelets <50,000
- Significant arterial atherosclerosis that would limit selective angiography
- Allergy to iodinated contrast agents that is not responsive to steroid management
- Active Infection or malignancy
- Appropriate candidate for knee replacement surgery determined by clinical and physical examination
- Recent (within 3 months) or active cigarette use
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: GAE OA
Subjects will be treated with a genicular artery embolization (GAE) procedure performed with Embozene Microspheres.
The microspheres will be delivered in a saline-contrast medium solution and will be delivered to the arteries supplying the areas of the subject's pain.
|
Embozene is a medical device made by Boston Scientific approved in the United States for the treatment of hypervascular tumors and arteriovenous malformations.
It consists of thousands of microscopic spheres that are injected into the artery in the knee going to the region of pain.
One of the causes of pain in the setting of knee arthritis is increased blood flow going to the specific area of pain.
The goal of this procedure is to decrease the blood flow (embolize) to the specific region of the knee that is causing your pain.
This is done by infusing Embozene particles into the specific blood vessel (genicular artery) supplying the area of pain in the knee.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Experiencing Treatment-related Adverse Events, as a Measure of Safety
Time Frame: Up to 12 Months after GAE
|
Treatment-related AEs from gennicular artery embolization during the study period
|
Up to 12 Months after GAE
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) as a Measure of Efficacy
Time Frame: Baseline, Month 1, Month 3, Month 6, Month 12
|
The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) is a self-administered questionnaire consisting of 24 items divided into 3 subscales. Each item is scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4). With a total possible range of 0-96, higher scores indicate worse pain, stiffness, and functional limitations. Pain (5 items, possible range 0-20): during walking, using stairs, in bed, sitting or lying, and standing upright Stiffness (2 items, possible range 0-8): after first waking and later in the day Physical Function (17 items, possible range 0-68): using stairs, rising from sitting, standing, bending, walking, getting in / out of a car, shopping, putting on / taking off socks, rising from bed, lying in bed, getting in / out of bath, sitting, getting on / off toilet, heavy domestic duties, light domestic duties |
Baseline, Month 1, Month 3, Month 6, Month 12
|
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Pain Subscale as a Measure of Efficacy
Time Frame: Baseline, Month 1, Month 3, Month 6, Month 12
|
The WOMAC Pain Subscale is a self-administered questionnaire of 5 items to assess Pain: during walking, using stairs, in bed, sitting or lying, and standing upright. Each item is scored on a scale of 0-4: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4), with a possible total score range of 0-20. |
Baseline, Month 1, Month 3, Month 6, Month 12
|
Change From Baseline in Visual Analog Scale (VAS) as a Measure of Efficacy
Time Frame: Baseline, Month 1, Month 3, Month 6, Month 12
|
The patient-reported severity of knee pain was quantified using a visual analog scale (VAS) score ranging from 0 (indicating no pain) through 10 (indicating the worst pain imaginable).
|
Baseline, Month 1, Month 3, Month 6, Month 12
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Siddharth Padia, M.D., University of California, Los Angeles
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18-000560
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Knee Osteoarthritis
-
LifeBridge HealthMicroPort Orthopedics Inc.; Rubin Institute for Advanced OrthopedicsRecruitingKnee Osteoarthritis | Osteoarthritis, Knee | Knee Pain Chronic | Arthropathy of Knee Joint | Knee Disease | Osteoarthritis Knees Both | Osteoarthritis Knee Left | Osteoarthritis Knee RightUnited States
-
University Hospital, Clermont-FerrandSanofiCompletedKnee Osteoarthritis (Knee OA)France
-
Jiangsu XinChen-Techfields Pharma Co., LTD.Completed
-
Novartis PharmaceuticalsRecruitingSymptomatic Knee OsteoarthritisUnited States, Spain, Hungary, Argentina, Germany, Slovakia, Czechia, Belgium, Romania
-
University of BathUniversity of Oxford; 3D Metal Printing Ltd; Versus ArthritisRecruitingMedial Knee OsteoarthritisUnited Kingdom
-
Max Biocare Pty. Ltd.Completed
-
University of IowaThe American Geriatrics SocietyCompletedKnee Osteoarthritis | Symptomatic Knee OsteoarthritisUnited States
-
Laval UniversityFonds de la Recherche en Santé du Québec; Natural Sciences and Engineering... and other collaboratorsCompleted
-
Chonbuk National University HospitalCompletedMild Knee OsteoarthritisKorea, Republic of
Clinical Trials on Embozene MicroSpheres
-
Brigham and Women's HospitalGuerbetWithdrawnArterial Occlusion | Knee Pain Chronic | Knee Swelling PainUnited States
-
University of VirginiaSiemens Medical SolutionsUnknownProstatic Hyperplasia | Hyperplasia | Male Urogenital Diseases | Prostatic Hypertrophy | Benign Prostatic Hyperplasia (BPH) | Genital Diseases, Male | Lower Urinary Tract Symptoms (LUTS) | ProstatismUnited States
-
University of North Carolina, Chapel HillCompletedOsteoarthritis Of KneeUnited States
-
Boston Scientific CorporationTerminated
-
NYU Langone HealthRecruiting
-
Varian, a Siemens Healthineers CompanyRecruitingKnee OsteoarthritisUnited Kingdom
-
Jena University HospitalBoston Scientific CorporationCompletedBenign Prostatic HyperplasiaGermany
-
University of California, Los AngelesVarian Medical SystemsRecruitingKnee Osteoarthritis | Degenerative Joint Disease of KneeUnited States
-
Palo Alto Veterans Institute for ResearchVarianNot yet recruitingOsteoarthritis, Knee | Osteoarthritis, Hip | Pain, Chronic | Synovitis | Osteo Arthritis Shoulders | Synovitis of Knee | Synovitis/Tenosynovitis - HipUnited States
-
NYU Langone HealthRecruiting